Global COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments and Vaccines - ResearchAndMarkets.com

DUBLIN--()--The "COVID-19 Pipelines - Cell Therapies, Diagnostics, Treatments, & Vaccines" report has been added to ResearchAndMarkets.com's offering.

This comprehensive report provides coverage of the rapidly evolving pandemic, with an emphasis on the emerging role of cell therapies in the prevention and management of the COVID-19.

While there is not yet an approved treatment for COVID-19, the scientific, medical, and regulatory agencies are making heroic efforts to bring out new medicines. Numerous COVID-19 product categories have emerged, including vaccines, antibodies, antivirals, repurposed drugs, RNA-based drugs, and cell-based therapies, as well as other approaches, such as enzymes, peptides, and glycoproteins. This report explores each of these product development categories in detail, presenting the products under development and timelines for them to come to market. Special attention is given to the critical role of cell-based therapies in the management of the global pandemic.

To accelerate the development of therapies against COVID-19, the repurposing of existing drugs is being explored by numerous market competitors. For example, Barcitinib is being explored because of its anti-inflammatory effect and possible ability to reduce viral entry. A specific dose of the anti-HIV combination, Lopinavir-Nitonavir, is now in clinical trials with Arbidol or Ribavirin. Remdesivir, developed by Gilead Sciences, was earlier tested in patients with Ebola virus and has shown promise in animal models for MERS and SARS. Remdesivir has reached Phase III in the U.S. and China.

Favipiravir, a purine nucleoside leading to inaccurate viral RNA synthesis, was previously developed by Toyama Chemical of Japan and has now been approved for a clinical trial as a drug for the treatment of COVID-19. Chloroquine has shown itself to be effective in treating COVID-19 in China. Dozens of companies are rushing vaccine development and proceeding toward clinical trials. As select examples, the U.S. NIH initiated a Phase I trial in Seattle evaluating an investigational vaccine (mRNA-1273) created by NIAID scientists and their collaborators at Moderna, Inc. Sanofi and Regeneron launched a Phase II/II trial in New York evaluating the IL-6 targeted Kevzara. Inovio Pharmaceuticals is advancing its vaccine into human trials within the U.S. and intends to produce one million doses of it by the end of the year.

Globally, the healthcare industry is using every weapon in its armory to suppress the threat from the virus, including the use of living therapies such as natural killer (NK) cells, T-cells, stem cells, and exosomes. While many novel approaches are being investigated, stem cells - mesenchymal stem cells (MSCs) in particular - are showing intriguing potential for the treatment of COVID-19.

COVID-19 Market Trends

The aim of this report is to gather existing research on COVID-19, reveal key insights, and position the reader to identify emerging market opportunities related to the Coronavirus pandemic. It provides comprehensive coverage of the outbreak, highlights global competitors involved in the fight against COVID-19, and presents product development pipelines, diagnostic testing approaches, vaccine development programs, regulatory approvals, and importantly, trend rate data for COVID-19 scientific publications, patents, and clinical trials on a worldwide basis.

With the rapidly developing nature of this global pandemic, you don't have the time to do the research. Claim this global strategic report to become immediately informed, without sacrificing hours of unnecessary research or lacking awareness of critical COVID-19 events.

Key Topics Covered:

  1. Report Overview
  2. Coronavirus: Structure, Infection, Replication, Symptoms
  3. Global Statistics On COVID-19
  4. Funding for COVID-19 Research
  5. Published Scientific Papers On COVID-19
  6. Patents of SARS and MERS With Possible Relevance To COVID-19
  7. Clinical Trials Landscape for COVID-19
  8. COVID-19's Negative/Posive Impacts On Healthcare Industry
  9. Medicines in Development for COVID-19
  10. Emerging Vaccine Treatments for COVID-19
  11. Antibody Therapies in Development for COVID-19
  12. Antiviral Drugs in Development for COVID-19
  13. Repurposed Drug Candidates Against COVID-19
  14. Cell-Based Therapies in Development for COVID-19
  15. Medical Devices in Development for COVID-19
  16. Commercially Available Diagnostics for COVID-19
  17. Market Analysis
  18. Cell Therapy Companies Joining forces Against COVID-19
  19. Other Companies/Institutions Sponsoring Trials for COVID-19

Companies Mentioned

  • AlloVir
  • AlloVir and Baylor College of Medicine
  • Aspire Health Science
  • Athersys, Inc
  • Banc de Sang i Teixits
  • Beijing 302 Hospital
  • BioNTech
  • Biostar Stem Cell Research Institute
  • BioXcellerator
  • Bonus BioGroup, Ltd.
  • Caladrius Biosciences
  • Camillo Ricordi
  • Capricor Therapeutics
  • CAR-T (Shanghai) Biotechnology, Co., Ltd
  • Celltex Therapeutics Corporation
  • Celularity Incorporated
  • Chinese Academy of Sciences
  • Citius Pharmaceuticals, Inc.
  • ClinicalTrials.gov
  • Cynata Therapeutics
  • CytoDyn
  • FibroGenesis
  • GC LabCell
  • Gilead Sciences
  • Global Institute of Stem Cell Therapy and Research (GIOSTAR)
  • Guangzhou Institute of Respiratory Disease
  • Healios KK
  • Hope Biosciences
  • Icahn School of Medicine/Mesoblast, Inc
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Kimera Labs, Inc.
  • Lattice Biologics, Ltd.
  • Lineage Cell Therapeutics, Inc.
  • Mesoblast, Ltd.
  • Moderna, Inc
  • NantKwest, Inc.
  • Orbsen Therapeutics
  • Organicell
  • Orgenesis
  • Peking University
  • Pluristem Therapeutics, Inc.
  • Regeneron
  • REMSTEM
  • Roche
  • Royan Institute
  • Sanofi
  • Stem Cells Arabia
  • Takeda
  • The Cure Alliance
  • Tianhe Stem Cell Biotechnologies, Inc
  • Toyama Chemical
  • University of Miami
  • Vir Biotechnology
  • Vitro Biopharma
  • World Health Organization (WHO)
  • Wuhan Hamilton Biotechnology
  • ZhiYong Peng

For more information about this report visit https://www.researchandmarkets.com/r/urcnss

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900